N-methyl-D-aspartate (NMDA) receptor activation, at the level of the spinal cord, has been shown to play an important role in the facilitation of nociception in several animal models. However, the use of NMDA antagonists as analgesics is limited by serious side effects due to nonselective effects among the NMDA receptor subtypes. Recent discoveries revealed that the transfection of small interfering RNAs (siRNAs) into animal cells resulted in the potent, long-lasting, post-transcriptional silencing of specific genes. Thus, we investigated the effect of intrathecal (i.t.) injection of siRNAs targeting NMDA-R2B receptor subunit protein (NR2B) receptors, a subunit of NMDA receptor, for the modulation of pain. The results indicate that the use of siRNA targeting the NR2B subunit not only decreased the expression of NR2B mRNA and its associated protein, as demonstrated by real-time PCR and Western blotting, but also abolished formalin-induced pain behaviors in rat model. The peak effect occurred on day 3 for mRNA and day 7 for its protein, following i.t. injection of 5 mg of siRNA-NR2B. These data prove the feasibility of i.t. siRNAs in the investigation of functional gene expression in the context of whole animal behavior for the management of chronic pain. Gene Therapy (2005) 12, 59-66.
Introduction
Spinal glutamate receptors play an important role in the facilitation and maintenance of nociception; a-amino-3-hydroxy-5-methyl-4-isoazole propionate and kinate receptors mediate monosynaptic reflexes; 1 and acute nociceptive responses. 2 Conversely, N-methyl-D-aspartate (NMDA) receptors are implicated in polysynaptic spinal pathways 3 and in chronic nociceptive responses. Spinal administration of NMDA evokes a dose-dependent, selective, and reversible hyperalgesia in mice and rats. 4 Additionally, increased spinal release of glutamate has been observed following various forms of peripheral nociceptive stimulation. 5 The role of NMDA receptor activation in animal models of chronic pain has also been established. Behavioral studies demonstrate that NMDA receptor antagonists profoundly inhibit the tonic phase (phase 2) of formalin-induced nociception. 6 Several genes encoding NMDA receptor subunits have been identified. These genes fall into three categories: NMDA-R1 (NR1), A-D isoforms of NMDA-R2 (NR2A-D), and NMDA-R3 subunit. 7 Functional NMDA-R2B receptor subunit protein (NR2B)-containing NMDA receptors are formed by their coassembly with the obligatory NR1 subunits. 8 NR1 subunits are ubiquitously expressed in the central nervous system (CNS), but the localization of NR2B subunits is more restricted and was initially described as forebrain specific. 9 Recently, NR2B protein was found in the spinal cord, where it was localized predominantly in the superficial dorsal horn. 10 Although the efficacy of NMDA receptor antagonists in various experimental and clinical pain situations has been well documented, their use as analgesics is limited by serious side effects. One promising approach to obtain safer NMDA receptor antagonist analgesics is to use subtype-selective NMDA receptor antagonism. Currently, the available pharmacological NMDA receptor antagonists are not uniquely selective for specific NMDA receptor subtypes. Therefore, the aim of the present study was to investigate the role of NR2B receptors for the modulation of pain using a more selective experimental tool. For this purpose, small interfering RNAs (siRNAs) able to inactive NR2B gene expression were used. Tuschl and co-workers reported that RNA interference (RNAi) can be elicited very effectively by welldefined 21-base duplex RNAs termed siRNAs. 11, 12 RNAi is based on the remarkable ability of double-stranded RNAs (dsRNA), which represent RNA duplexes of specific length and structure that finally guide sequence-specific degradation of mRNAs homologous in sequence to siRNAs, to induce sequence-specific gene silencing in vivo. 12, 13 siRNA can transiently inactivate a single gene and, therefore, can inactivate receptor functions in a more specific and selective manner than receptor antagonists. The effects on antinociceptive processes of NR2B siRNA were evaluated in rats by means of the formalin test. In this study, we attempted to deliver siRNA of NR2B with a polyethyleneimine (PEI)-based gene-delivery system into the subarachnoid space to induce an analgesic effect in a formalin test in rats.
Results
Effects of knockdown of the NR2B subunit on motor coordination and acute thermal stimuli Based on the suggestion by Elbashir SM et al, 32 we used the unrelated gene dsRNA of green fluorescent protein (dsRNA-GFP) as the control group. The rotarod test measured the ability of a rat to maintain balance and motor coordination. 14 Motor coordination was not affected by intrathecal (i.t.) administration of PEI alone, GFP, or NR2B siRNA when compared to the untreated group ( Figure 1a) . Next, we determined the effect of i.t. PEI alone, GFP, or NR2B siRNA on noninjury-inducing noxious stimuli, which was the latency response to an acutely painful thermal stimulus delivered to the paw. Compared to the responses of the untreated group, the administration of PEI alone, GFP, or NR2B siRNA did not alter the latency of paw withdrawal from a painful thermal stimulus (Figure 1b ).
NR2B siRNA injection reduces the pain response to the formalin test
Subcutaneous injections of 1% formalin produce two phases of nociceptive behavioral patterns. The first phase (acute phase) begins immediately following formalin injection and lasts 3-5 min, followed by a period of 10-15 min when the animals display very little nociceptive behavior. The second phase (tonic phase) starts approximately 15-20 min following formalin injection and lasts for 20-40 min.
The nociceptive response in the acute phase was indistinguishable among all groups for nociception with regard to the flinching response. The NR2B siRNA significantly decreased the nociceptive response in the tonic phase, 7 and 14 days after administration of a 5-mg dose of i.t. siRNA-NR2B, compared to response at 7 and 14 days after administration of PEI 0.9 ml (Figure 2 ) that is correlated with the diminished protein level of NR2B subunit shown in Western blotting (Figure 4) . Compared with 5 mg dsRNA-GFP and untreated groups, the NR2B siRNA also significantly decreased the nociceptive response in the tonic phase 7 days after i.t. administration of a 5 mg siRNA-NR2B. At 21 days after administration of 5 mg siRNA-NR2B, the flinching response in the tonic phase resolved (Figure 2 ). The formalin test performed on the 3rd day after i.t. administration of 1 and 5 mg of siRNA-NR2B were not significantly different from the control groups.
siRNA injection silences the NR2B gene
To examine the effect of siRNA injection on gene expression, we used real-time reverse transcriptase (RT)-PCR and Western blotting. Gene expression of NR2B was analyzed at different time points in all groups of rats injected with NR2B dsRNA, PEI alone, GFP dsRNA, or untreated as described in Materials and methods. There were no significant differences in mRNA and protein level of NR2B among the control groups. The decreased level of mRNA and protein of NR2B at different time points after injection of siRNA-NR2B were expressed as the percentage of mRNA and protein level detected in the controls 7 days after being treated with the corresponding transfection agent alone. PEI-delivered siRNA-NR2B affected NR2B mRNA downregulation in a dose-dependent manner (Figure 3a) . At 3 days after transfection, 5 mg of siRNA-NR2B resulted in 84% inhibition of NR2B mRNA compared with the mock control (7 days PEI alone) (Figure 3a) . The inhibition of NR2B mRNA lasted about 14 days and recovered on the 21st day (Figure 3b ). The effect was specific, as injection Intrathecal NR2B siRNA for formalin pain P-H Tan et al of siRNA targeting GFP did not change NR2B mRNA level (Figure 3a) , and siRNA-NR2B treatment did not affect the mRNA level of formalin-induced nociceptionrelated subunits including NR1, NR2A, and NR2C ( Figure 3c ). Downregulation by siRNA-NR2B was confirmed at the protein level ( Figure 4 ) by Western blotting and immunodetection using an anti-NR2B antibody. At 7 days after transfection, 5 mg of siRNA-NR2B induced 83% downregulation of the NR2B protein. The downregulation of NR2B protein level persisted 14 days and recovered on the 21st day. The nociceptive response induced by formalin was also decreased during the period of downregulation of NR2B protein.
siRNA decreased NR2B immunohistochemical stain in spinal cord
Significant reduction of NR2B immunoreactivity and some staining in the deeper laminae in the dorsal horn of the spinal cord were detected after 7 days treated by NR2B siRNA (Figure 5c ). In contrast, in the GFP-siRNAtreated spinal cord of control group, significant NR2B immunoreactivity was observed in the superficial laminae of the dorsal horn 7 days after i.t. injection of GFPsiRNA ( Figure 5a and b).
Discussion
In the absence of a specific inhibitor for a receptor, the antisense approach was recently employed in vitro and in vivo to specifically inhibit gene expression and to study its function. However, the well-documented nonspecific effects of antisense oligonucleotide treatment complicate interpretation of studies employing antisense technology. 15 As an alternative to the antisense approach, gene expression can be specifically inhibited by homologous dsRNA. The process, referred to as RNAi, was originally discovered and has been most extensively studied in Caenorhabditis elegans 13, 16 and Drosophila melanogaster. 12, 17 Biochemical studies in Drosophila cells and embryo extracts led to the discovery of mechanistic details of RNAi, showing that long dsRNA is processed injection of 0.9 ml of PEI+5 mg of GFP siRNA as the control; Lane 4-7: 3, 7, 14, and 21 days, respectively, after i.t. injection of 0.9 ml of PEI+5 mg of NR2B siRNA. Five rats were used for every time point. Values are the mean7s.e.m. Note peak effect at day 7 after injection of 5 mg of NR2B siRNA. *Po0.05 compared to control groups.
Intrathecal NR2B siRNA for formalin pain P-H Tan et al by a nuclease named 'dicer' into 21-to 23-nt duplexes termed siRNAs. Subsequently, siRNAs associate with an RNA-induced silencing complex nuclease complex and guide this multicomponent enzyme to degrade mRNA in a sequence-specific manner. A similar process occurs in mammalian early embryos and embryonal cell lines. 18 Synthetic siRNA duplexes introduced by cationic lipidmediated transfection, electroporation, or microinjection, and intracellular expression of siRNAs from plasmid DNA [19] [20] [21] are now commonly used laboratory methods. The natural biological process of RNAi, thus, provides a new approach for downregulation of gene expression in mammalian cell systems. In this study, gene expression of the NR2B subunit was inhibited by i.t. (subarachnoid) delivery of siRNA-NR2B evidenced by decreased RNA and protein shown through real-time RT-PCR, Western blotting, and immunohistochemical staining of spinal cord specimens. The specific functional consequences of the NR2B deletion demonstrate the distinct advantages of the use of siRNA to produce a spatiotemporal gene knockdown in the CNS. Also, these data provided novel evidence that siRNA can be used in the investigation of functional gene expression in the context of whole animal behavior, regardless of the availability of targeted mutation technologies.
Injury of tissue generates a complex cascade of transmitters and modulators in the dorsal horn that initiate activity-dependent neuroplastic changes that result in pain hypersensitivity. 22 Activation of NMDA channels allow a large Na + and Ca 2+ influx through the postsynaptic membrane that produces a cascade of molecular events leading to central sensitization, which includes the activation of protein kinases that phosphorylate membrane-bound NMDA receptors, resulting in changes in NMDA receptor channel kinetics and reduction in its voltage-dependent Mg 2+ block, 23 subsequently enhancing responsiveness to synaptically released glutamate. 24 This increase in responsiveness to synaptically released glutamate causes pain hypersensitivity far beyond the site and the duration of the C fiber activating stimulus. 25 The formalin test is the most frequently used method for assessing the antihypersensitivity efficacy of NMDA receptor antagonists. 6 The immediate response to intraplantar formalin reflects the activation of primary afferent nociceptors. 26 The latter response, phase 2, reflects a continuing stimulation of peripheral nociceptors, 26 and central sensitization triggered by the phase 1 input from the periphery. 6, 22 During the second phase, there is a low, but nonzero level of peripheral afferent activity. 27 Examination of the firing of dorsal horn neurons reveals a prominent biphasic response pattern with the first phase corresponding to the initial elevation in afferent input, while the second phase is believed to reflect a state of facilitated processing driven by the moderate ongoing peripheral input. 2 Afferent input evokes release of excitatory amino acids and peptides that lead to the initiation of a state of facilitation, mediated in part by activation of NMDA subtype glutamate receptors. 4 Pharmacological studies using centrally applied receptor antagonists indicate a contribution of NMDA receptors in the behavioral response seen during phase 2 of formalin. 6 The formalin test has been used widely as a model of inflammatory pain, 6, 28 and is different from most models of pain in that it is possible to assess the way an animal responds to In this study, we found that that motor coordination, as indicated by the rotarod test, was not affected by the siRNA-NR2B-induced analgesic effect. Similar to a previous study, 29 we found that siRNA-mediated NR2B mRNA silencing was transient and did not persist longer than 21 days, as monitored by real-time RT-PCR and Western blotting at the protein level. In the Song's study, 29 mRNA levels and protein expression in the siRNA-treated mice were only 40% of those in control mice on day 14, and returned to normal 20 days after the last injection. However, different from the Song's study, 29 the peak effect of inhibition of NR2B protein expression (7 days) was later than that of NR2B mRNA inhibition (3 days) following injection of 5 mg siRNA-NR2B in this study. The interval between the peak inhibition of mRNA and protein expression may reflect the relative slow degradation and long half-lives of the NR2B subunit which have been measured for about 20 h (2177 h). 30 The values suggest that the regulation of synthesis is not an efficient mechanism for rapid modulation of the levels of NMDA receptors in neurons. Furthermore, in this study, the inhibition of NR2B gene expression by siRNA was efficient but not complete. The result may be due to uptake of siRNA by cells of the superficial dorsal horn and not by deep laminae cells, as shown in the immunohistochemical staining of the spinal cord in this study. Our results also showed about 83% downregulation of NR2B mRNA and protein expression, which is consistent with a previous study. 31 We designed the siRNA according to the Tuschl design rule (target sites beginning with AA, 3 0 -UU overhangs for both the sense and antisense siRNA strands, approximately 50% G/C content, 50-100 nucleotides downstream of the start codon) 32 by selecting the target mRNA from the 70th to 90th nucleotide downstream of the start codon with 47.6% G/C content. The siRNA designed based on the Tuschl rule may be more efficient in inhibition of targeted mRNA expression.
Cells did not take up siRNA duplexes in the absence of the transfection agent. A previous study has demonstrated that synthetic siRNA could be delivered by a cation lipid-mediated transfection such as oligofectamine 31 and DOTAP, 33 but not by liposome-mediated transfection. Important research has been moving toward the development of polycation-based gene-delivery systems such as PEI conjugates designed to minimize nuclease degradation through the design of vectors with the capacity to escape the endosomal-lysosomal pathway. The concept of the 'proton sponge' hypothesizes that polymers such as PEI with buffering capacities can buffer endosomes and potentially induce their rupture. 34, 35 In this study, PEI, a cationic polymer, protected RNA and induced endosomal swelling and rupture before RNA breakdown, thus providing in vivo superior transfection efficiencies similar to cationic lipids 36, 37 ; it worked well with siRNA duplexes. To our best knowledge, our study is the first trial of not only injecting siRNA into subarachnoid space in vivo but also using PEI to transfect RNA, providing another available transfection agent for introducing siRNA into target cells in vivo.
Development of efficient methods for introducing active siRNAs into target cells in vivo could be the key issue in treating genetic and acquired diseases using this novel strategy. Another limitation of synthetic siRNAmediated RNAi in human cells is that it is transitory, with cells recovering from a single treatment. To circumvent this problem, plasmids encoding siRNAs that were driven by RNA polymerase (pol) III promoter have been developed and found to silence gene expression in cultured cells. 20, 21 This promoter can also be manipulated such that it is susceptible to repression by the tetracycline-repressor system. 38 In contrast to the knockout technique, the vector-based RNAi systems achieve loss of function phenotypes without the loss of genomic information of the targeted gene. This leaves the possibility to restore the exact expression of the endogenous gene once the RNAi vector is silenced or removed and to turn the expression of a gene on-and-off at will. This will provide a possible novel method for short-or long-term management of pain in the future.
RNAi is a more promising system than gene-knockout mice because groups of genes can be simultaneously rendered ineffective without the need for time-consuming crosses. Gene therapy currently depends on the ectopic expression of exogenous proteins; however, RNAi may eventually complement this gain-of-function approach by silencing disease-related genes with siRNAs. Our study of i.t. siRNA-NR2B delivery targeting a pain-related gene with cationic polymer transfection not only provided the evidence of application of i.t. siRNA in the investigation of spinal cord functional gene expression in the context of whole animal behavior but also could be tailored to take advantage of developing gene therapies for pain in a clinical context.
Materials and methods

Synthesis of dsRNA
The dsRNAs were carefully designed and subjected to a Blast-Search (National Center for Biotechnology Information Database) against the expressed sequence Tag (EST) libraries to ensure that only one gene was being targeted. The 19 nucleotide duplex and 2 unpaired nucleotide overhang of 3 0 end as follows:
Chemically synthetic dsRNA against the NR2B receptor and GFP were synthesized by Dharmacon Research Incorporation (Lafayette, CO, USA).
Polymer conjugate synthesis
Branched PEIs were purchased from Sigma Corporation (St Louis, MO, USA) and were used without further purification. The PEI (45 mg) was dissolved in 10 ml of 5% dextrose in water (D5W) (pH 6.5) (0.45% PEI; 100 mM). Relative amounts of RNA to carrier were as follows: for the ratio of PEI:RNA, six equivalents of PEI Intrathecal NR2B siRNA for formalin pain P-H Tan et al nitrogen per RNA phosphate, that is, 0.18 ml of 100 mM PEI solution per mg of RNA. 39 RNA-polymer complexes were allowed to form for 10 min at room temperature before injection.
Animals
A total of 58 male Sprague-Dawley rats, weighing 250-350 g, were used with adherence to the guidelines for pain research. 40 In all, 15 rats were housed per cage. The cages were placed in the experimental room 24 h before testing for acclimatization. The rats were fed a standard laboratory diet and tap water ad libitum and kept at 23711C with a 12-h light/dark cycle. All animal protocols were approved by the Institute Review Board of the Chang Gung Memorial Hospital.
I.t. cannulation
The placement of i.t. catheters in rats was previously described by Yaksh and Rudy. 41 Cannulae were implanted under halothane anesthesia. Through an incision in the atlanto-occipital membrane, polyethylene tubing (PE-5) was advanced caudally, extending to the rostral edge of the lumbar enlargement. After implantation of the tubing, rats were housed singly. I.t. injections were performed 2 days following the implantation surgery. Only animals with normal motor function were used.
The rats were randomly assigned to different groups: (1) dsRNA-NR2B: low-dose group (1 mg, n ¼ 5) and highdose group (5 mg, n ¼ 5). All treatments were administered 3 days prior to formalin injection. (2) Recovery periods: 7, 14, and 21-day recovery groups (5 mg dsRNA-NR2B 7, 14, and 21 days before formalin testing, n ¼ 5 rats in 14, 21 days group and n ¼ 7 rats in 7 days group). (3) Control groups: 5 mg dsRNA-GFP (n ¼ 7), the vehicle group (0.9 ml PEI, n ¼ 7), and the untreated group (n ¼ 5) were used as the controls for each group of NR2B dsRNA. The agents (PEI and dsRNA-GFP) were injected 7 days before the formalin test in all of the control groups, except the rats in the untreated group that received no treatment before the formalin test. Additionally, the vehicle groups (0.9 ml PEI 3, 14, and 21 days before the formalin test, n ¼ 4 in each group) were used as control for recovery comparisons. The rats in the control groups and 5 mg dsRNA-NR2B 7-day recovery group were further evaluated by behavior testing including rotarod performance and paw-withdrawal latency before the formalin test. Spinal cords were dissected immediately after formalin testing in each group for use in real-time RT-PCR, Western blotting, and immunohistochemical staining of spinal cord sections.
Behavioral tests Motor coordination. Each rat was first trained on the morning before the test to remain for 30 s on a Ugo Basile rotarod apparatus revolving at 12 r.p.m. The rats were then placed on a rotarod set at 40 r.p.m. The length of time (in s) that the rat remained on the rod was measured. A cutoff of 60 s was observed.
14 Thermal paw-withdrawal threshold. Thermal paw withdrawal was assessed using a thermal nociceptive stimulus. 42 Animals were placed in a Plexiglas cage, placed on a preheated glass plate maintained at 301C for 10 min for adaptation. A radiant thermal stimulus was focused on the midplantar surface of the hindpaw and the latency (0.1 s) with a maximum cutoff of 20 s for the withdrawal of the paw from the heat source was determined.
Formalin assay. Persistent pain produced by peripheral tissue injury can be modeled by the formalin test. Injection of a dilute formalin solution into the paw evokes a spontaneous behavior, characterized by paw flinching that persists for approximately 1 h. Following recovery from cannulation, rats received i.t. administration of either PEI, NR2B, GFP dsRNA, or no treatment as above. The animals were tested to evaluate the behavioral responses to formalin injection. Rats were gently restrained and the dorsal surface of the hindpaw was injected with 50 ml of a 1% formalin solution. The contralateral paw was not injected. Following injection, animals were immediately transferred to a Plexiglas observation cage. Each rat was observed and the number of paw flinches were counted during the first 5 min, and then for 1 min in every 5 min until 60 min following formalin injection.
RNA isolation and real-time RT-PCR
RNA was isolated and purified from individual spinal cords using the GeneStrips Reagent (RNAture, Irvine, CA, USA). In all, 52 rats were used in these experiments. cDNA synthesis was performed by reverse transcription of each sample using random hexamer primers and the BcaBEST RNA PCR kit (TaKaRa Biomedicals Company). Real-time PCR was performed using the ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA) with SYBR Green detection in a two-step reaction. The following PCR program was used: stage 1, 501C, 2 min; stage 2, 951C, 10 min; stage 3, 40 cycles, each consisting of 15 s at 951C and 60 s at 601C. The program ended at 251C. r36B4 was used as a reference gene, As NR1 and NR2 subunits of NMDA receptor except NR2D participate in the development of formalin-induced nociception. 43 PCR primers for NR1 and NR2 subunits of NMDA receptor except NR2D were used as given in Table 1 . Standard conditions for PCR (25 ml) were 10 ng of template, 1 Â SYBR Green PCR Master Mix, forward and reverse primers (2.5 mM), and water (sterile and UV crosslinked) to the final volume. Primer concentrations for r36B4 were 800 nM each. The PCR setup was singleplex, that is, the target and reference genes, as well as RT and ÀRT transcripts were detected in separate tubes. A 'no-template' control was used for each primer pair consisting of water (sterile and UV crosslinked). After completion, expected sizes of PCR products were confirmed on 3% NuSieve 1:3 agarose (BMA, Rockland, ME, USA) analytical gels.
Results of the RT-PCR analysis were expressed as C T values, which were used to determine the amount of target gene mRNA in relation to the amount of reference gene mRNA (see ABI Prism 7700 Sequence Detection System User Bulletin 2). DC T indicated the difference between the number of cycles necessary to detect the PCR products for NR1, each NR2 subunit, and the reference gene. DDC T was the difference between the DC T of the transfection agent-alone group and the DC T 's of the other injection groups. Data were expressed as 2 ÀDDC T to
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give an estimate of the amount of target mRNA present in the tissue relative to the transfection agent-alone group.
Western blots
Total proteins from the spinal cord segment were prepared by addition 500 ml of ice-cold solubilization buffer (150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 5 mM EDTA, and 1% Triton X-100) containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride and 5 mg/ml each of pepstatin, leupeptin, chymostatin, antipain, and aprotinin). The tissue was homogenized with a homogenizer. After being placed on ice for 30 min, the homogenate was centrifuged at 10 000 g for 5 min at 41C. The supernatant was collected and assayed for protein content using the BCA assay method (Pierce, Rockford, IL, USA) and stored at À201C until further use. Total protein (15 mg) was electrophoresed on a 6% sodium dodecylsulfate-polyacrylamide gel using sample buffer, running buffer, and molecular weight standards, as suggested by the manufacturer. After electrophoresis, the proteins were and transferred to a PVDF membrane and blocked with 5% nonfat dry milk. The primary antibody (1:200 dilution of rabbit polyclonal anti-NMDA-R2B; Chemicon, Temecula, CA, USA) was added for 2 h at room temperature in fresh blocking buffer. The membranes were washed for 30 min in washing buffer at room temperature, before the secondary antibody (1:16 000 dilution of horseradish peroxidase-coupled goat anti-rabbit immunoglobulin G; Sigma) was added for 1 h at room temperature in blocking buffer. The membranes were washed in washing buffer for another 30 min, and the antibodies were then revealed using Western Blot Chemiluminescence Reagent Plus (NEN, Boston, MA, USA). For densitometric analyses, blots were scanned and quantified with Quantity One analysis software (Bio-Rad, Hercules, CA, USA), and the results were expressed as the ratio of NMDA-R2B immunoreactivity to a-tubulin immunoreactivity.
Immunohistochemistry of spinal cord sections
Following behavioral testing, the rats were anesthetized with pentobarbital (100 mg/kg, intraperitoneally), and transcardially perfused with 0.1 M phosphate-buffered saline (PBS) solution (400 ml) followed by 4% paraformaldehyde in PBS. After 2 h, the spinal cords were removed and postfixed in 4% formalin in PBS for 4 h. Following postfixation, the tissue was cryoprotected with 30% sucrose overnight. Frozen sections (10 mm) were blocked with 2% normal goat serum in PBS for 2 h at room temperature, followed by overnight incubation at 41C in mouse affinity-purified anti-NR2B AB (1:100; Chemicon). Following overnight incubation, the sections were incubated for 1 h at room temperature in goat antirabbit-fluorescein isothiocyanate (1:250 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA, USA). Image analysis was performed with a Nikon eclipse E800 fluorescence microscope (Nikon instech company, Kawasaki, Japan) coupled to an RT slider cool digital camera (Diagnostic instruments Inc., Sterling Heights, MI, USA) and an image-analyzing system (advanced spot software; Diagnostic instruments Inc.).
Statistical analysis
All data are expressed as the mean7standard error of the mean (s.e.m.). Data from the rotarod test, thermal test, formalin test, and NMDA-R2B gene expression were analyzed using one-way analysis of variance, with Dunnett's post hoc test to determine significant differences between groups. A P-value of less than 0.05 was considered statistically significant. . The rNR2A-C subunit primer sequences were derived from the European Molecular Biology Laboratory (EMBL) nucleotide sequences with accession numbers AF001423, U11419, and U08259, respectively. b r36B4 primers were derived from the rat acidic ribosomal phosphoprotein P0 mRNA sequence, EMBL accession number X15096.
